CoChat
Sign Up
Cited by 98

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

miR-196a Ameliorates Phenotypes of Huntington Disease in Cell, Transgenic Mouse, and Induced Pluripotent Stem Cell Models

Cheng, Pei-Hsun, Li, Chia-Ling, Chang, Yu-Fan, Tsai, Shaw-Jeng, Lai, Yen-Yu, Chan, Anthony W.S., Chen, Chuan-Mu, Yang, Shang-Hsun·2013·The American Journal of Human Genetics
DOI 10.1016/j.ajhg.2013.05.025
Open this paper in CoChat — free account

Abstract

Huntington disease (HD) is a dominantly inherited neurodegenerative disorder characterized by dysregulation of various genes. Recently, microRNAs (miRNAs) have been reported to be involved in this dysregulation, suggesting that manipulation of appropriate miRNA regulation may have a therapeutic benefit. Here, we report the beneficial effects of miR-196a (miR196a) on HD in cell, transgenic mouse models, and human induced pluripotent stem cells derived from one individual with HD (HD-iPSCs). In the in vitro results, a reduction of mutant HTT and pathological aggregates, accompanying the overexpression of miR-196a, was observed in HD models of human embryonic kidney cells and mouse neuroblastoma cells. In the in vivo model, HD transgenic mice overexpressing miR-196a revealed the suppression of mutant HTT in the brain and also showed improvements in neuropathological progression, such as decreases of nuclear, intranuclear, and neuropil aggregates and late-stage behavioral phenotypes. Most importantly, miR-196a also decreased HTT expression and pathological aggregates when HD-iPSCs were differentiated into the neuronal stage. Mechanisms of miR-196a in HD might be through the alteration of ubiquitin-proteasome systems, gliosis, cAMP response element-binding protein pathway, and several neuronal regulatory pathways in vivo. Taken together, these results show that manipulating miR-196a provides beneficial effects in HD, suggesting the potential therapeutical role of miR-196a in HD.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ajhg.2013.05.025

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Research works printed but not linked: 17

  1. 1993, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes, Cell, 72, 971, 10.1016/0092-8674(93)90585-E · DOI · Paper page
  2. Yang, 2011, Transgenic animal models of Huntington’s disease, Current Topics in Behavioral Neurosciences, 7, 61, 10.1007/7854_2010_105 · DOI
  3. Li, 2004, Huntingtin and its role in neuronal degeneration, Neuroscientist, 10, 467, 10.1177/1073858404266777 · DOI
  4. Junn, 2012, MicroRNAs in neurodegenerative diseases and their therapeutic potential, Pharmacol. Ther., 133, 142, 10.1016/j.pharmthera.2011.10.002 · DOI · Paper page
  5. Yu, 2008, MicroRNA miR-124 regulates neurite outgrowth during neuronal differentiation, Exp. Cell Res., 314, 2618, 10.1016/j.yexcr.2008.06.002 · DOI
  6. Yang, 2008, Towards a transgenic model of Huntington’s disease in a non-human primate, Nature, 453, 921, 10.1038/nature06975 · DOI
  7. Cheng, 2013, Significantly differential diffusion of neuropathological aggregates in the brain of transgenic mice carrying N-terminal mutant huntingtin fused with green fluorescent protein, Brain Struct. Funct., 218, 283, 10.1007/s00429-012-0401-x · DOI
  8. Jeon, 2012, Neuronal properties, in vivo effects, and pathology of a Huntington’s disease patient-derived induced pluripotent stem cells, Stem Cells, 30, 2054, 10.1002/stem.1135 · DOI
  9. Chiang, 2010, Modulation of energy deficiency in Huntington’s disease via activation of the peroxisome proliferator-activated receptor gamma, Hum. Mol. Genet., 19, 4043, 10.1093/hmg/ddq322 · DOI
  10. Lin, 2001, Neurological abnormalities in a knock-in mouse model of Huntington’s disease, Hum. Mol. Genet., 10, 137, 10.1093/hmg/10.2.137 · DOI
  11. Sugars, 2004, Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington’s disease that contributes to polyglutamine pathogenesis, J. Biol. Chem., 279, 4988, 10.1074/jbc.M310226200 · DOI
  12. Marambaud, 2009, Calcium signaling in neurodegeneration, Mol. Neurodegener., 4, 20, 10.1186/1750-1326-4-20 · DOI
  13. Gaughwin, 2011, Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington’s disease, Hum. Mol. Genet., 20, 2225, 10.1093/hmg/ddr111 · DOI · Paper page
  14. Hou, 2010, MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins, Hepatology, 51, 1494, 10.1002/hep.23401 · DOI
  15. Miyazaki, 2012, Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2, Nat. Med., 18, 1136, 10.1038/nm.2791 · DOI
  16. Chen, 2011, MicroRNA-196: critical roles and clinical applications in development and cancer, J. Cell. Mol. Med., 15, 14, 10.1111/j.1582-4934.2010.01219.x · DOI
  17. Sinha, 2011, Micro RNA -214,-150,-146a and-125b target Huntingtin gene, RNA Biol., 8, 1005, 10.4161/rna.8.6.16035 · DOI · Paper page

Cited by

Sorted by citations

See all 98

Metadata

Authors
Cheng, P.-H., Li, C.-L., Chang, Y.-F., Tsai, S.-J., Lai, Y.-Y., Chan, A. W. S., Chen, C.-M., & Yang, S.-H.
Venue
The American Journal of Human Genetics
Publisher
Elsevier BV
Published
2013-08
Volume
93
Issue
2
Pages
306-312
ISSN
0002-9297
DOI
10.1016/j.ajhg.2013.05.025
Cited by
98
References
2
Language
en
Licence
Funders
  • National Cheng Kung University (NSC 97-3122-B-006-011)
  • Ministry of Education
  • National Science Council (NSC 101-2627-B-006, NSC 99-2320-B-006-026-MY3)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: miR-196a Ameliorates Phenotypes of Huntington Disease in Cell, Transgenic Mouse, and Induced Pluripotent Stem Cell Models. https://app.cochat.ai/papers/10.1016/j.ajhg.2013.05.025
The paper
Cheng, P.-H., Li, C.-L., Chang, Y.-F., Tsai, S.-J., Lai, Y.-Y., Chan, A. W. S., Chen, C.-M., & Yang, S.-H. (2013). miR-196a Ameliorates Phenotypes of Huntington Disease in Cell, Transgenic Mouse, and Induced Pluripotent Stem Cell Models. The American Journal of Human Genetics. https://doi.org/10.1016/j.ajhg.2013.05.025